Biogen has announced its decision to advance an experimental Alzheimer's drug, Diranersen, into late-stage Phase 3 testing despite disappointing results from mid-stage trials. The drug, which targets tau, a protein linked to Alzheimer's disease, did not demonstrate improved responses at higher doses.
However, Biogen noted that there are indications the treatment may reduce tau levels and slow cognitive decline, particularly at lower doses. Dr. Priya Singhal, Biogen's head of development, expressed optimism about the findings, highlighting the combination of tau reduction and cognitive benefits as critical factors for proceeding to Phase 3.
This development is part of Biogen's ongoing efforts in Alzheimer's research, which has seen mixed results in the past, including the controversial withdrawal of its first drug, Aduhelm. Biogen's other Alzheimer's treatment, Leqembi, also targets amyloid, another protein associated with the disease.
The competitive landscape includes rival Eli Lilly, which is also exploring tau-targeting therapies. Biogen's move to Phase 3 could have significant implications for the company and the broader Alzheimer's treatment market, as successful outcomes could enhance its position in a challenging sector